Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expans...
2020年2月24日 - 10:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced that its partner,
Bristol-Myers Squibb, has initiated a randomized Phase 2 cohort
expansion in its ongoing first-in-human Phase 1/2a trial of the
anti-CTLA-4 Probody BMS-986249 alone and in combination with
Opdivo® (nivolumab). BMS-986249 is a peptide masked version of the
anti-CTLA-4 antibody Yervoy® (ipilimumab). The randomized cohort
expansion is designed to further evaluate the safety and efficacy
of BMS-986249 in combination with Opdivo® in patients with
metastatic melanoma, as part of the larger clinical trial
(NCT03369223). The advancement of BMS-986249 into this part of the
planned study triggers a milestone payment of $10 million from
Bristol-Myers Squibb to CytomX.
In September 2019, Bristol-Myers Squibb also initiated the dose
escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a
second anti-CTLA-4 Probody, BMS-986288, based on a modified version
of ipilimumab, administered as monotherapy and in combination with
nivolumab in patients with selected advanced solid
tumors.
These Probody programs, designed to optimize the risk-benefit
profile of CTLA-4-directed therapy, arose from the companies’
foundational 2014 worldwide oncology license and collaboration
agreement.
“CTLA-4 is the prototypical checkpoint target and blocking this
mechanism has proven highly effective in the treatment of melanoma
and other cancer types. This exciting progress within our alliance
with Bristol-Myers Squibb is aimed at the development of
anti-CTLA-4 therapies to broaden the reach of this foundational
pathway for cancer patients,” said Sean McCarthy D.Phil.,
president, chief executive officer and chairman of CytomX
Therapeutics. “This ongoing work by the Bristol-Myers Squibb team
complements CytomX’s own work and continued clinical progress with
the combination of our anti-PD-L1 Probody, CX-072, with ipilimumab,
which will further delineate the potential of our Probody
therapeutic platform to deliver differentiated anti-cancer
therapies.”
Additional details on the Phase 1/2a trial of BMS-986249 are
available at ClinicalTrials.gov using the Identifier
NCT03369223.
Additional details on the Phase 1/2a trial of BMS-986288 are
available at ClinicalTrials.gov using the Identifier
NCT03994601.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. As leaders in the
field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential best-in-class
immunotherapies against clinically validated targets and potential
first-in-class therapeutics against novel, difficult to drug
targets. Five novel drug-candidates utilizing our Probody
technology are in clinical trials, with three in Phase 2 studies
and two in Phase 1. These clinical programs include cancer
immunotherapies against validated targets such as a PD-L1-targeting
Probody therapeutic wholly owned by CytomX (CX-072) and a
CTLA-4-targeting Probody therapeutic partnered with Bristol Myers
Squibb (BMS-986249). The CytomX clinical stage pipeline also
includes first-in-class Probody drug conjugates against previously
undruggable targets, including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen and BMS. For
additional information about CytomX Therapeutics, visit
www.cytomx.com and follow us on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely
on any of these forward-looking statements, including those
relating to the potential benefits, safety and efficacy of CytomX’s
or any of its collaborative partners’ product candidates,
administered separately or in combination, the potential benefits
or applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing
clinical trials of CX-072 and CX-2009, and the timing of any
future clinical trials to be initiated by CytomX or its
collaborative partners. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX and its partners have five product candidates utilizing
CytomX’s Probody platform in the initial stages of clinical
development and its other product candidates are currently in
preclinical development, and the process by which preclinical and
clinical development could potentially lead to an approved product
is long and subject to significant risks and uncertainties; the
possibility that the results of early clinical trials may not be
predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; CytomX’s dependence on the
success of CX-072, CX-2009, CX-2029 and BMS-986249; CytomX’s
reliance on third parties for the manufacture of the company’s
product candidates; and possible regulatory developments in the
United States and foreign countries. Additional applicable risks
and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in CytomX’s
Quarterly Report on Form 10-Q filed with the SEC on November 7,
2019. The forward-looking statements contained in this press
release are based on information currently available to CytomX and
speak only as of the date on which they are made. CytomX does not
undertake and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a registered trademark of CytomX Therapeutics.
Yervoy and Opdivo are registered trademarks of Bristol-Myers
Squibb.
Contact:
Investors and Media:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024